Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H11F3N2O5
CAS Number:
Molecular Weight:
296.20
NACRES:
NA.51
PubChem Substance ID:
UNSPSC Code:
41106305
EC Number:
200-722-8
MDL number:
Assay:
≥99% (HPLC)
Biological source:
synthetic
Form:
powder
Solubility:
water: 50 mg/mL, clear, colorless
Storage temp.:
−20°C
Product Name
Trifluorothymidine, ≥99% (HPLC)
InChI
1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
InChI key
VSQQQLOSPVPRAZ-RRKCRQDMSA-N
SMILES string
OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F
biological source
synthetic
assay
≥99% (HPLC)
form
powder
mp
190-193 °C (lit.)
solubility
water: 50 mg/mL, clear, colorless
storage temp.
−20°C
Quality Level
Related Categories
Application
Trifluorothymidine has been used as a component of selection medium to screen thymidine kinase (TK) mutants in lymphoma cells, human lymphoblastoid TK6 cells, and L5178Y mouse lymphoma cells.
Biochem/physiol Actions
Trifluorothymidine is a thymidine analog and is light sensitive. TFT serves as a thymidine kinase substrate to study enzyme specificity and kinetics. Incorporation of phosphorylated TFT into DNA induces damage, making it useful for DNA repair studies. TFT may also be used in the inhibition of thymidylate synthase and in screening mutant thymidine kinase gene.. It elicits antitumor activity in gastrointestinal (GI) cancers and has therapeutic potential to treat herpetic keratitis.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
signalword
Warning
hcodes
Hazard Classifications
Carc. 2 - Muta. 2 - Repr. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Marc Peeters et al.
Future oncology (London, England), 14(16), 1629-1645 (2018-04-28)
Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article
Olaf H Temmink et al.
Molecular cancer therapeutics, 9(4), 1047-1057 (2010-04-08)
Trifluorothymidine (TFT) is part of the novel oral formulation TAS-102, which is currently evaluated in phase II studies. Drug resistance is an important limitation of cancer therapy. The aim of the present study was to induce resistance to TFT in
A A Carmine et al.
Drugs, 23(5), 329-353 (1982-05-01)
Trifluridine (trifluorothymidine) is an antiviral agent for topical use in the eye, and is structurally related to idoxuridine. In vitro studies have shown that it effectively inhibits the replication of herpes simplex virus type 1, which causes primary keratoconjunctivitis and
Novel cell death mechanisms of trifluorothymidine.
Bijnsdorp IV, Kruyt F, et al.
Nucleic Acids Symposium Series, 52, 649-649 (2008)
Connie Kang et al.
Drugs, 79(14), 1583-1590 (2019-09-07)
Trifluridine/tipiracil (Lonsurf®) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor. Trifluridine/tipiracil has recently been granted an additional indication in the USA for the treatment of metastatic gastric cancer, including gastroesophageal junction
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service